BRIEF—Recordati acquires consumer brands from Bayer

Italian drugmaker Recordati has purchased three Bayer Consumer Health brands for the French market.

Two of these, Transipeg and TransipegLib, are macrogol-based laxatives for the treatment of symptomatic constipation in adults, and the third brand, Colopeg, is a large volume bowel cleanser indicated in preparation for endoscopic exploration.

Financial terms of the transaction were not disclosed.

The 2016 net sales of the products in France amount to around 10 million euros ($11.7 million).

“The acquisition of Transipeg, TransipegLib and Colopeg which are well‐known brands in France, is in line with our strategy to reinforce our product portfolio in this market,” says Andrea Recordati, chief executive and vice chairman.

“We are progressively enhancing our presence in the area of gastroenterology and this line of products provides further product choice for doctors and patients in order to meet their specific needs,” he added.